NCT04063501
Longitudinal Evaluation of Microbial and Host Signatures During Immunotherapy for Lung Cancer
At risk: Primary completion moved at least 11 months later.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 9 versions: 8 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Notable Primary completion pushed from Dec 2026 to Dec 2027
- Eligibility criteria expanded, about 8 words
- Study completion pushed from Feb 2027 to Feb 2028
- Minor Enrollment target: 40 to 48v8
- Notable Primary completion date: Dec 2024 to Dec 2026
- Enrollment target: 30 to 40
- Study completion date: Feb 2026 to Feb 2027
- Notable Enrollment target: 80 to 30v6
- Minor Primary completion date: Sep 2024 to Dec 2024
- Study completion date: Sep 2024 to Feb 2026
- Start date: Mar 2, 2021 to Feb 9, 2021
- Site contact updated
Show 2 earlier versionsHide 2 earlier versions
- Notable Start date: Sep 1, 2020 to Mar 2, 2021v4
- Notable Trial status: Not Yet Recruiting to Recruiting
- Primary and study completion dates: Sep 2020 to Sep 2024
- Start date changed from estimate of Sep 2019 to Sep 1, 2020
- Site details revised
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Progression-free survival (PFS)
Timeframe: 3 Years
Microbiota signatures in lower and upper airways
Timeframe: 3 Years
Microbiota signatures in stool
Timeframe: 3 Years
Arms and interventions
Advanced stage unresectable Non-Small Cell Lung Cancer
Adult patients with a diagnosis of advanced stage unresectable Non-Small Cell Lung Cancer and indication for PD-1 blockade treatment (either as monotherapy or combined with chemotherapy)
Other: Bronchoscopy, Research Procedures
Sites
1 site in 1 country
- NYU Langone HealthNew York, New York, United States